Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions

Molecular Pharmacology

Volumn 67, Issue 6, 2005, Pages 2016-2024

  Mukhopadhyay, Somnath ^a   Howlett, Allyn C ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; DEACETYLLEVONANTRADOL; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; INDOLE DERIVATIVE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; METHANANDAMIDE; PROTEIN SUBUNIT; PYRAZOLE; RIMONABANT; CANNABINOID; LIGAND; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG POTENTIATION; METABOLISM; RAT; TUMOR CELL LINE;

ANIMALS; CANNABINOIDS; CELL LINE, TUMOR; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; LIGANDS; MORPHOLINES; NAPHTHALENES; RATS; RECEPTOR, CANNABINOID, CB1;

EID: 21744437960     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.003558     Document Type: Article

References (39)

1. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
2. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. s. J Pharmacol Exp Ther 294:539-547.
5. Brown PJ and Schonbrunn A (1993) Affinity purification of a somatostatin receptor-G-protein complex demonstrates specificity in receptor-G-protein coupling. J Biol Chem 268:6668-6676.
6. Clark WA, Jian X, Chen L, and Northup JK (2001) Independent and synergistic interaction of retinal G-protein subunits with bovine rhodopsin measured by surface plasmon resonance. Biochem J 358:389-397.
7. Clarke WP and Bond RA (1998) The elusive nature of intrinsic efficacy. Trends Pharmacol Sci 19:270-276.
8. 2 dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype. J Biol Chem 276:28667-28675.
9. Downes GB and Gautam N (1999) The G protein subunit gene families. Genomics 62:544-552.
10. Faivre S, Regnauld K, Bruyneel E, Nguyen QD, Mareel M, Emami S, and Gespach C (2001) Suppression of cellular invasion by activated G-protein subunits Gαo, Gαi1, Gαi2 and Gαi3 and sequestration of Gβγ. Mol Pharmacol 60:363-372.
11. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, and Kobilka BK (1997) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272:2587-2590.
12. 2 Receptors. Mol Pharmacol 56:1362-1369.
13. Gudermann T, Kalkbrenner F, and Schultz G (1996) Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol 36:429-459.
14. Heithier H, Frohlich M, Dees C, Baumann M, Haring M, Gierschik P, Schiltz E, Vaz WL, Hekman M, and Helmreich EJ (1992) Subunit interactions of GTP-binding proteins. Eur J Biochem 204:1169-1181.
15. Houston DB and Howlett AC (1993) Solubilization of the Cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol Pharmacol 43:17-22.
16. Houston DB and Howlett AC (1998) Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. Cell Signal 10:667-674.
17. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
18. Howlett AC, Mukhopadhyay S, Shim JY, and Welsh WJ (1999) Signal transduction of eicosanoid CB1 receptor ligands. Life Sci 65:617-625.
19. Howlett AC, Song C, Berglund BA, Wilken GH, and Pigg JJ (1998) Characterization of CB1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies. Mol Pharmacol 53:504-510.
20. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
21. Kenakin T and Onaran O (2002) The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23:275-280.
22. Lachance M, Ethier N, Wolbring G, Schnetkamp PP, and Hebert TE (1999) Stable association of G proteins with beta 2AR is independent of the state of receptor activation. Cell Signal 11:523-533.
23. Law SF and Reisine T (1992) Agonist binding to rat brain somatostatin receptors alters the interaction of the receptors with guanine nucleotide-binding regulatory proteins. Mol Pharmacol 42:398-402.
24. Law SF and Reisine T (1997) Changes in the association of G protein subunits with the cloned mouse δ opioid receptor on agonist stimulation. J Pharmacol Exp Ther 281:1476-1486.
25. Leff P, Scaramellini C, Law C, and McKechnie K (1997) A three-state receptor model of agonist action. Trends Pharmacol Sci 18:355-362.
26. 1 cannabinoid receptor. Biochem Pharmacol 60:1315-1323.
27. Mukhopadhyay S and Howlett AC (2001) CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains. Eur J Biochem 268:499-505.
28. 1 cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. Mol Pharmacol 57:162-170.
29. 1 cannabinoid receptor-G protein association: a possible mechanism for differential signaling. Chem Phys Lipids 121:91-109.
30. O'Shannessy DJ and Hoffman WL (1987) Site-directed immobilization of glycoproteins on hydrazide-containing solid supports. Biotechnol Appl Biochem 9:488-496.
31. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 54:1064-1072.
32. Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, and Graham RM (1996) Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol 49:112-122.
33. Prather PL, Martin NA, Breivogel CS, and Childers SR (2000) Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein α-subunits with different potencies. Mol Pharmacol 57:1000-1010.
34. Sim-Selley LJ, Brunk LK, and Selley DE (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135-143.
35. Skrzydelski D, Lhiaubet AM, Lebeau A, Forgez P, Yamada M, Hermans E, Rostene W, and Pelaprat D (2003) Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 64:421-429.
36. Vasquez C and Lewis DL (1999) The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 19:9271-9280.
37. Waelbroeck I (1999) Kinetics versus equilibrium: the importance of GTP in GPCR activation. Trends Pharmacol Sci 20:477-481.
38. Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, Woulfe D, and Brass LF (2002) Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem 277:46035-46042.
39. Yang Q and Lanier SM (1999) Influence of G protein type on agonist efficacy. Mol Pharmacol 56:651-656.